ClinicalTrials.gg
RecruitingNCT07732426Updated Jul 28, 2026

Effects of Semaglutide on Brain Dopamine Responses to Food Cues in Adults With Obesity and Food Addiction Tendencies

An interventional study of Semaglutide in Food Addiction Tendency, Obesity and Overweight, sponsored by Seoul National University Hospital. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Basic science

How we know · 4 judgments

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
19 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 145 studies testing semaglutide in Obesity — 70 open to participants now, 79 under way, 15 of them phase 3. Semaglutide · Obesity.

Planned enrollment
125th of 145
30 · median 100
Started
2026
with 29 others
No phase
18 of 145
14 open now
Primary completion
2028-02
later than 50 of 78 live
Registered
125th of 145
by date

Among the 145 studies testing semaglutide in Obesity, this one is the 125th largest by planned enrollment, is one of 30 that started in 2026, is one of 18 with no phase, reaches primary completion later than 50 of the 78 other live ones, and was the 125th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

70 of the 145 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

64 more — sign in →

By country, each count listing its studies:

All 70 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 19 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 145 studies testing semaglutide in Obesity, or all of them as a file.
02

Study summary

The goal of this clinical trial is to investigate how semaglutide affects the way the brain responds to food in adults with obesity and food addiction tendencies.

The main goals of this study are:

  • To see if semaglutide changes dopamine-related activity in the brain during the look, smell, and drink period.
  • To see if semaglutide changes dopamine-related brain signals during the post-ingestive period.
  • To see if semaglutide changes psychological survey results and cognitive task results.

Adults with obesity and food addiction tendencies will join this study. Each participant will receive semaglutide treatment for 8 weeks. Each participant will have two brain scans using [11C]raclopride PET.

During each PET scan, participants will:

  • View food images.
  • Receive chocolate milk through a tube while lying in the scanner.
  • Use a tablet during the scan to rate their hunger, desire for the chocolate milk drink, and liking of the drink.
Read the detailed description
  1. Background and Rationale

    GLP-1 receptor agonists, including semaglutide, are effective treatments for obesity. However, the brain mechanisms underlying their effects on appetite, food reward, and eating behavior remain incompletely understood. Food-related visual and olfactory cues may engage dopamine-mediated reward pathways during the pre-ingestive phase, and post-ingestive signals may further influence dopamine signaling after food intake.

    This study will use [11C]raclopride positron emission tomography (PET) to assess dopamine-related binding measures in the human brain. The study will examine whether semaglutide changes dopamine-related brain responses during food cue and drink exposure and during the post-ingestive period.

  2. Study Protocol and Procedures

This is a prospective clinical trial using a 2-by-2 crossover design. Participants will receive once-weekly semaglutide treatment for 8 weeks and will undergo two [11C]raclopride PET scans. The scans will be performed under conditions with and without the effect of semaglutide, depending on group assignment.

Before each PET imaging session, participants will complete baseline assessments, including body measurements, psychological surveys, and computer-based cognitive tasks. [11C]raclopride will then be administered according to the PET protocol. Participants will undergo brain PET imaging while lying in the scanner.

During the imaging session, participants will complete a standardized chocolate milk drink task. This task includes a baseline period, exposure to chocolate milk images, smelling the chocolate milk drink, and the post-ingestive stage using the chocolate milk drink delivered through a tube. During the scan, participants will use a tablet to rate hunger, desire for the chocolate milk drink, and liking of the drink at set time points.

The same PET task procedures will be used across study conditions. This will allow researchers to compare dopamine-related PET measures, psychological survey results, and cognitive task results between conditions with and without the effect of semaglutide.

03

Conditions studied

  • Food Addiction Tendency
  • Obesity
  • Overweight
04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants aged between 19 and 50 years.
  • Eligible for treatment with semaglutide, defined as either:
  • Initial (BMI) of 30 kg/m2 or higher; or
  • Initial BMI of 27 kg/m2 to less than 30 kg/m2 with at least one weight-related comorbidity, such as dysglycemia, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.
  • Mild or greater food addiction tendency, defined as a Yale Food Addiction Scale (YFAS) score of 3 or higher.
  • Able to understand the study tasks and provide appropriate responses.

Exclusion criteria

Exclusion Criteria:

  • Use of medications that may affect body weight or dopaminergic medications within the past 2 months.
  • Known to semaglutide.
  • Pregnant, breastfeeding, or planning to become pregnant.
  • Severe renal impairment, hepatic impairment, heart failure, acute pancreatitis, or thyroid disease.
  • Any medical condition, disease, or medical history that, in the investigator's judgment, would make it difficult for the participant to complete the study or would interfere with interpretation of the study results.
  • Allergy to ingredients in chocolate milk, including milk or soy, or to ingredients that may be present through cross-contamination, including egg, buckwheat, peanut, wheat, peach, tomato, walnut, pork, or beef.
  • Participants with both no self-reported preference for chocolate milk and a chocolate milk preference score of less than 5 on a 10-point visual analog scale (VAS).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Off Drug then On Drug

    Participants undergo a baseline \[11C\]raclopride PET scan before semaglutide treatment. They then receive an 8-week semaglutide dose-escalation treatment, followed by a second \[¹¹C\]raclopride PET scan at the end of treatment.

    Drug: Semaglutide

  • Experimental
    On Drug then Off Drug

    Participants first receive an 8-week semaglutide dose-escalation treatment and undergo a \[¹¹C\]raclopride PET scan at the end of treatment. After an 8-week washout period, they undergo a second \[¹¹C\]raclopride PET scan.

    Drug: Semaglutide

Interventions

  • Participants receive an 8-week subcutaneous semaglutide dose-escalation treatment using Wegovy: 0.25 mg once weekly for the first 4 weeks, followed by 0.5 mg once weekly for the next 4 weeks.

    Also known as: Wegovy

06

What researchers measure

Primary outcomes

  1. Change in Dopamine Binding Potential During the Look, Smell, and Drink Period

    Dopamine D2/D3 receptor binding potential is measured using \[11C\]raclopride PET during the food cue and drink period. The outcome is the within-participant difference in binding potential between the on-drug and off-drug/post-washout conditions.

    Time frame: Group A: At Baseline (Day 0) and 8 weeks (±3 days) after starting semaglutide. Group B: At 8 weeks (±3 days) after starting semaglutide and 8 weeks after semaglutide discontinuation.

Secondary outcomes

  1. Change in Dopamine Binding Potential During the Post-Ingestive Period

    Dopamine D2/D3 receptor binding potential is measured using \[11C\]raclopride PET during the post-ingestive period after the drink. The outcome is the within-participant difference in binding potential between the on-drug and off-drug/post-washout conditions.

    Time frame: Group A: At Baseline (Day 0) and 8 weeks (±3 days) after starting semaglutide. Group B: At 8 weeks (±3 days) after starting semaglutide and 8 weeks after semaglutide discontinuation.

  2. State Food Craving Score

    State food craving is assessed using the General Food Cravings Questionnaire-State (G-FCQ-S). Each of the 15 items is evaluated on a 0 to 100 scale, where higher scores indicate greater intensity of the felt state.

    Time frame: Immediately before and after PET imaging. Group A: At Baseline (Day 0) and 8 weeks (±3 days) after starting semaglutide. Group B: At 8 weeks (±3 days) after starting semaglutide and 8 weeks after semaglutide discontinuation.

  3. Chocolate Milk Liking, Chocolate Milk Wanting, and Fullness Ratings (VAS-100)

    Liking and wanting for the chocolate milk stimulus, as well as general fullness, are assessed repeatedly during PET imaging using 0-to-100 visual analogue scale ratings. For liking and wanting, higher scores indicate greater liking of or desire for the chocolate milk stimulus. For fullness, higher scores indicate greater subjective fullness. Ratings are collected at 15 predefined time points during each PET scan.

    Time frame: During each 92-minute PET scan, at 10, 20, 30, 40, 50, 51, 54, 57, 60, 65, 70, 75, 80, 85, and 90 minutes.

  4. Food-Specific Attentional Bias

    Food-specific attentional bias is assessed using a computer-based dot-probe task with webcam-based eye tracking. Bias is calculated from reaction time differences between probes replacing food versus neutral images, and from gaze-based measures including dwell time toward food versus neutral images and first saccade direction. Higher values indicate greater attentional bias toward food stimuli.

    Time frame: Before PET imaging. Group A: At Baseline (Day 0) and 8 weeks (±3 days) after starting semaglutide. Group B: At 8 weeks (±3 days) after starting semaglutide and 8 weeks after semaglutide discontinuation.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared publicly because the current protocol does not include a plan for public sharing of individual participant data. Participant data will be managed in accordance with the approved protocol and institutional privacy protection requirements.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Feb 2028, 19 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 19 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2026
First posted
Jul 28, 2026
StartActual
Jul 15, 2026
Primary completionEst.
Feb 29, 2028
CompletionEst.
Jun 30, 2028
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07732426
Responsible party
Hyung Jin Choi (Professor, Seoul National University Hospital) — Principal investigator
First posted
Jul 28, 2026
Start date
Jul 15, 2026
Primary completion
Feb 29, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Jul 28, 2026

Study contacts

Taesung Lee, MD
Contact
nova2123@snu.ac.kr
+821097262123
Hyung Jin Choi, MD, PhD
principal investigator · Seoul National University College of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion